Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL16027128 | 0.91 | TLR8 (0.41) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| SCHEMBL31497044 | 0.87 | DHFR (0.47) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| SCHEMBL9326441 | 0.83 | ALDH1A1 (0.38) | CYP3A4ALOX5MAPTTP53TSHR | |
| SCHEMBL14003767 | 0.83 | PTGS2 (0.53) | TLR8CYP3A4TP53PTGS2HTR2A | |
| SCHEMBL5372853 | 0.83 | TLR8 (0.41) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| Hydroxyamine SCHEMBL27830404 | 0.82 | ALOX5 (0.40) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| SCHEMBL9766396 | 0.81 | TLR8 (0.43) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| SCHEMBL5377508 | 0.81 | TLR8 (0.40) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| SCHEMBL5377737 | 0.81 | TLR8 (0.43) | TLR8CYP3A4ALOX5MAPTMEN1 | |
| SCHEMBL5374367 | 0.81 | TLR8 (0.40) | TLR8CYP3A4ALOX5MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226015-A9 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE MULTI-TARGETED ANTIGENS | UNIV COLORADO REGENTS (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024141921-A1 | TUMOUR NECROSIS FACTOR ALPHA DOMAIN ANTIBODY | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) | 2024-07-04 | — | — | WO | disclosed |
| US-20240141030-A1 | VEGF-BINDING MOLECULES | BOEHRINGER INGELHEIM INT (DE) | 2024-05-02 | — | — | US | disclosed |
| US-20240130973-A1 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE MULTI-TARGETED ANTIGENS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-04-25 | — | — | US | disclosed |
| US-11932702-B2 | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor | ABLYNX N.V. (BE) | 2024-03-19 | — | — | US | disclosed |
| US-20240026013-A2 | CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | ABLYNX N.V. (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20240002497-A1 | NAV1.7 BINDERS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230416404-A1 | FACTOR X BINDERS ENHANCING FX ACTIVATION | NOVO NORDISK AS (DK) | 2023-12-28 | — | — | US | disclosed |
| US-11840566-B2 | Methods of treating asthma with polypeptides targeting IL-13 and TSLP | ABLYNX N.V. (BE) | 2023-12-12 | — | — | US | disclosed |
| EP-4272822-A2 | ADAMTS BINDING IMMUNOGLOBULINS | Merck Patent GmbH (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20080063657-A1 | antigen and flagellin which lacks a hinge region; antigen and flagellin are components of a fusion protein; pathogen-associated molecular pattern (PAMP) and a flavivirus; West Nile, Langat, Kunjin, Murray Valley encephalitis, Japanese encephalitis, Tick-borne encephalitis, Yellow fever viral proteins | VAXINNATE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| WO-2007118134-A2 | A SERUM-FREE VIRUS PROPAGATION PLATFORM FOR A VIRUS VACCINE CANDIDATE | MEDIMMUNE, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1841785-A2 | COMPOSITIONS COMPRISING PATHOGEN-ASSOCIATED MOLECULAR PATTERNS AND ANTIGENS AND THEIR USE TO STIMULATE AN IMMUNE RESPONSE | Vaxinnate Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070224205-A1 | Compositions that include hemagglutinin, methods of making and methods of use thereof | VAXINNATE CORPORATION | 2007-09-27 | — | — | US | disclosed |
| WO-2007103322-A2 | COMPOSITIONS THAT INCLUDE HEMAGGLUTININ, METHODS OF MAKING AND METHODS OF USE THEREOF | VAXINNATE CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1831259-A2 | COMPOSITIONS OF INFLUENZA VIRAL PROTEINS AND METHODS OF USE THEREOF | Vaxinnate Corporation (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007079448-A2 | THREE COMPONENT CARBOHYDRATE VACCINE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070092518-A1 | Anti-TNFalpha antibodies and methods of use | EVANS GLEN A | 2007-04-26 | — | — | US | disclosed |
| WO-2006078657-A2 | COMPOSITIONS COMPRISING PATHOGEN-ASSOCIATED MOLECULAR PATTERNS AND ANTIGENS AND THEIR USE TO STIMULATE AN IMMUNE RESPONSE | VAXINNATE CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006069262-A2 | COMPOSITIONS OF INFLUENZA VIRAL PROTEINS AND METHODS OF USE THEREOF | VAXINNATE CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026013-A2 | CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | CX3CR1, CCR5, CXCR3 | TLR8 690/4885CYP3A4 4825/4885ALOX5 4736/4885 |
| US-20070224205-A1 | Compositions that include hemagglutinin, methods of making and methods of use thereof | TLR3, TLR5, TLR7 | TLR8 8/4885CYP3A4 4762/4885ALOX5 2760/4885 |
| US-20240141030-A1 | VEGF-BINDING MOLECULES | VEGFA, KDR, FLT1 | TLR8 1146/4885CYP3A4 4784/4885ALOX5 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.